The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So melanoma is BRAF inhibitor monotherapy improved survival to the tune of a nine-month improvement in overall survival, which in melanoma, which is median survival used to be six to nine months, so on average six to nine months. So like getting a bump like that. You're basically doubling the survival of patients with metastatic melanoma, but not curing.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.